Anika Therapeutics, Inc. ANIK

About Anika Therapeutics, Inc. (ANIK): stock profile, AI score and financials

Anika Therapeutics, Inc. (ANIK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANIK at 31.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,416 of 2,925 stocks — the bottom half of the AI-ranked universe. ANIK scores in the top quartile across earnings quality (75.3). Areas of concern include revenue growth (13.1) and institutional flow (14.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Anika Therapeutics, Inc. reports quarterly revenue of $32.6M, net income of $3.3M, an operating margin of 9.1%. Top institutional holders of ANIK by reported 13-F value include BlackRock, Caligan Partners, MORGAN STANLEY, based on the most recent SEC filings. ANIK trades on the Nasdaq exchange and files with the SEC under CIK 898437. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANIK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Anika Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 898437 →